Paroxetine Prolonged Release Tablets IP 12.5 MG – Roxetis 12.5 Tablets

Product Description

Paroxetine Prolonged Release Tablets IP 12.5 MG – Roxetis 12.5 Tablets contain Paroxetine, a selective serotonin reuptake inhibitor (SSRI) that acts by inhibiting serotonin reuptake in the central nervous system, thereby enhancing serotonergic activity. The prolonged-release formulation is designed to control the release of the active ingredient over time. Paroxetine is prescribed for selected psychiatric conditions, including depression and certain anxiety-related disorders.

Target Speciality

• Psychiatry
• Neuropsychiatry
• Distinctive Features 

SSRI Class: Belongs to the selective serotonin reuptake inhibitor class of antidepressants.

Serotonergic Mechanism: Acts through the inhibition of serotonin reuptake in the central nervous system.

Prolonged-Release Formulation: Designed to provide controlled drug release over time.

Psychiatric Application: Indicated for selected depressive and anxiety-related disorders.

Disclaimer

This information is for general reference only and does not replace professional medical advice. To be administered only under medical supervision. Not for public promotion.

FAQs

1. What are the formulation characteristics of ROXETIS 12.5 Tablets?

ROXETIS 12.5 is a prolonged-release formulation containing Paroxetine, an SSRI.

2. What is the packaging of ROXETIS 12.5 Tablets?

The product is supplied in 10 × 10 packaging.

3. Is monopoly available for ROXETIS 12.5 Tablets?

Yes. District-wise monopoly rights are offered across India. Please contact our team to confirm availability in your district.

4. Is ROXETIS 12.5 manufactured at a WHO-GMP-certified facility?

Yes. Manufacturing follows GLP, WHO, ISO and GMP norms, and every batch is assayed for actual content before dispatch. 

5. What is the minimum order quantity (MOQ) for ROXETIS 12.5 Tablets?

The minimum order quantity is subject to business terms and availability. Please contact our team for confirmation.